==> picture [224 x 35] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: [email protected] Website: www.biotron.com.au

16 November 2022

The Manager Companies ASX Limited 20 Bridge Street SYDNEY NSW 2000

(13 pages by email)

Dear Madam,

PRESENTATION TO ANNUAL GENERAL MEETING

I attach a Chairman’s Address and a PowerPoint presentation to be delivered at today’s Annual General Meeting which is convened to be held at 11.00 am.

This announcement has been approved by the Company’s Managing Director.

Yours faithfully

==> picture [107 x 69] intentionally omitted <==

Peter J. Nightingale Company Secretary

pjn11456

==> picture [224 x 35] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: [email protected] Website: www.biotron.com.au

16 November 2022

CHAIRMAN’S ADDRESS TO THE AGM

My Fellow Shareholders

After an enforced three year absence it is a pleasure to return to a face to face meeting with shareholders.

It is more than ironic that a company focused on antiviral solutions finds itself so severely buffeted by a pandemic for which we have the temerity to suggest we may have a future medical solution.

To understate the case considerably, conducting clinical trials during COVID has been enormously challenging. Only the extraordinary effort by Biotron management, staff, consultants and trial associates has ensured that the Company not only survived but emerged in a hearteningly strong position.

We did not escape entirely unscathed. Our programs suffered a six month delay which, considering the forces amassed against us, was a remarkably good outcome. That delay is the reason we have again turned to you, our shareholders, for assistance in the current capital raising round.

Before the end of the current financial year, the Company expects to deliver results from three Phase 2 clinical trials. Two trials target HIV and, subject to funding availability, one trial will target COVID. Additionally, the Company hopes to produce results from a further COVID clinical sub-study.

In any normal year, one such trial is an onerous undertaking.

While we have high hopes for successful COVID trial outcomes, HIV remains the Company’s primary objective. The current HIV trials are pivotal to Biotron’s near term commercialisation aspirations.

These trials were specifically designed and undertaken to address questions from potential partners on how our lead compound, BIT 225, could fit into the HIV landscape. The anticipated data is key to providing necessary answers.

Full details of these undertakings will be discussed during the Managing Director’s presentation.

We also remain unwavering in our belief that the Company’s Hepatitis B program has the potential to achieve longer term success in an arena which has substantial unmet need.

Biotron is a small Australian biotechnology company with international ambitions. The markets we expect to enter are huge. This drives our conservative, step-wise strategy. The science at the core of the Company’s endeavours is unquestionably sound. Our results to date speak for themselves. Nine successful clinical trials soothe natural anxieties about anticipated outcomes during the next immediate period.

The data to be generated in the next six months is the result of many years of hard work and substantial investment. We approach it with confidence and more than a little sense of excitement.

Sincerely

==> picture [166 x 74] intentionally omitted <==

Michael J. Hoy Chairman

BIOTRON LIMITED (ASX:BIT)

Annual General Meeting 16 November 2022

==> picture [615 x 51] intentionally omitted <==

==> picture [346 x 51] intentionally omitted <==

This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Biotron Limited, are intended to identify forward‐looking statements. By their nature, forward‐looking statements involve risk and uncertainty because they reflect Biotron’s current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.